Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared. This study retrospectively evaluated 373 patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatol Commun
Main Authors: Choi, Won‐Mook, Choi, Jonggi, Lee, Danbi, Shim, Ju Hyun, Lim, Young‐Suk, Lee, Han Chu, Chung, Young‐Hwa, Lee, Young‐Sang, Park, Sook Ryun, Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Lee, So Jung, Kim, Kang Mo
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327222/
https://ncbi.nlm.nih.gov/pubmed/32626838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1523
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados